Pavan Kalyan

Tankala Pavan Kalyan is a technology entrepreneur building AI-driven solutions for the life sciences and pharmaceutical industry. He is the founder of Ritivel, an AI-native regulatory platform that automates the creation of FDA submission documents with 100% reproducibility and word-level traceability. A graduate of the Indian Institute of Technology, Bombay, Pavan brings expertise in AI engineering combined with regulatory domain knowledge to solve the "last mile" problem in drug development. Ritivel was accepted into Y Combinator's Winter 2026 batch. The company's technology enables pharmaceutical, biotech, and CRO teams to draft Clinical Study Reports (CSRs), CTD modules, and other regulatory documents in minutes instead of weeks.

Ritivel is an AI-native regulatory platform for life sciences that automates the creation of FDA submission documents. The platform transforms raw clinical trial data into complete regulatory documents such as Clinical Study Reports (CSRs) and CTD modules in minutes rather than the traditional 8-12 weeks of manual work. What sets Ritivel apart is its 100% reproducibility (same input always produces the same output), word-level traceability linking every generated sentence to clinical evidence, and 100% on-premise deployment to keep sensitive patient data within the client's infrastructure. The platform addresses the "last mile" of drug development, a problem that generic AI tools cannot solve because they lack understanding of regulatory standards and FDA requirements. Clinical development is pharma's biggest bottleneck, with trial timelines increasing 33% over the last decade despite rising R&D spend. By accelerating clinical timelines by 20%, companies can unlock hundreds of millions in additional revenue per drug through extended patent life.